Want to see HEWA full AI Analyst Report?
Top Page
HealthWarehouse
(OTC:HEWA)
Select Model
Select Model
Rating:39Underperform
Price Target:
$0.06
▼(-54.17% Downside)
Action:Reiterated
Date:09/19/26
The score is driven primarily by weak financial performance—TTM revenue decline, renewed losses, negative operating/free cash flow, and a persistently negative equity position. Technical indicators also remain bearish with the stock trading below all key moving averages and negative MACD (despite oversold RSI). Valuation offers limited support because the negative P/E reflects losses and there is no dividend yield data.
Positive Factors
Online pharmacy platform
The online pharmacy model gives HealthWarehouse a defined channel for reaching consumers with prescription and over-the-counter products. Its established platform and permitted fulfillment model provide a foundation for serving recurring healthcare demand over the medium term.
Negative Factors
Sharp revenue contraction
The sharp TTM revenue decline shows that recent demand or sales execution has weakened after earlier growth. A smaller revenue base reduces operating leverage and makes it harder to absorb fixed costs, sustain investment, or return to consistent profitability over the next several quarters.
Read all positive and negative factors
Positive Factors
Negative Factors
Online pharmacy platform
The online pharmacy model gives HealthWarehouse a defined channel for reaching consumers with prescription and over-the-counter products. Its established platform and permitted fulfillment model provide a foundation for serving recurring healthcare demand over the medium term.
Read all positive factors
HealthWarehouse (HEWA) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$3.34M
Dividend YieldN/A
Average Volume (3M)18.22K
Price to Earnings (P/E)―
Beta (1Y)-0.34
Revenue Growth-42.51%
EPS Growth-481.03%
CountryUS
Employees121
SectorHealthcare
Sector Strength45
IndustryMedical - Pharmaceuticals
Share Statistics
EPS (TTM)-0.02
Shares Outstanding57,190,910
10 Day Avg. Volume30,146
30 Day Avg. Volume18,220
Financial Highlights & Ratios
PEG Ratio0.89
Price to Book (P/B)-1.88
Price to Sales (P/S)0.13
P/FCF Ratio5.83
Enterprise Value/Market Cap2.96
Enterprise Value/Revenue0.32
Enterprise Value/Gross Profit0.70
Enterprise Value/Ebitda-33.83
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
HealthWarehouse Business Overview & Revenue Model
Company Description
HealthWarehouse.com, Inc. functions as a digital and direct-mail pharmaceutical service. Its offerings encompass a broad spectrum of pharmaceutical items, including generic and brand-name prescription drugs, specialized medications for pets, and a...
HealthWarehouse Financial Statement Overview
Summary
Income Statement
38
Negative
Balance Sheet
22
Negative
Cash Flow
33
Negative
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.73M | 48.99M | 33.61M | 20.28M | 18.14M | 16.14M |
| Gross Profit | 14.09M | 17.14M | 13.69M | 12.17M | 11.94M | 11.13M |
| EBITDA | -292.08K | 931.62K | 338.42K | -1.28M | -559.33K | -224.76K |
| Net Income | -915.87K | 265.00K | -332.97K | -1.77M | -952.03K | -572.50K |
Balance Sheet | ||||||
| Total Assets | 4.57M | 5.88M | 5.05M | 3.21M | 3.97M | 3.62M |
| Cash, Cash Equivalents and Short-Term Investments | 1.07M | 2.21M | 1.13M | 567.96K | 1.04M | 2.18M |
| Total Debt | 3.52M | 2.90M | 3.84M | 2.09M | 3.04M | 2.15M |
| Total Liabilities | 8.53M | 9.18M | 9.08M | 7.21M | 7.00M | 6.41M |
| Stockholders Equity | -3.95M | -3.30M | -4.04M | -4.01M | -3.03M | -2.79M |
Cash Flow | ||||||
| Free Cash Flow | -843.05K | 1.06M | 565.36K | -473.81K | -1.14M | 313.64K |
| Operating Cash Flow | -783.85K | 1.16M | 705.26K | -163.84K | -624.45K | 400.51K |
| Investing Cash Flow | -59.20K | -95.23K | -139.90K | -309.97K | -512.85K | -86.86K |
| Financing Cash Flow | 0.00 | 9.00K | 0.00 | 0.00 | 0.00 | 0.00 |
HealthWarehouse Technical Analysis
Negative
0.12
Price Trends
0.09
Negative
0.11
Negative
0.11
Negative
Market Momentum
>-0.01
Positive
25.22
Positive
2.47
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HEWA, the sentiment is Negative. The current price of 0.12 is above the 20-day moving average (MA) of 0.08, above the 50-day MA of 0.09, and above the 200-day MA of 0.11, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 25.22 is Positive, neither overbought nor oversold. The STOCH value of 2.47 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HEWA.
HealthWarehouse Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $7.20M | -0.76 | -224.80% | ― | ― | 98.17% | |
47 Neutral | $15.60M | -0.98 | -816.25% | ― | -27.70% | 61.44% | |
44 Neutral | $26.45M | -0.88 | -91.67% | 9.40% | -19.67% | 34.91% | |
42 Neutral | $102.67M | -4.19 | -179.12% | ― | -16.73% | -143.95% | |
39 Underperform | $3.34M | -2.86 | 25.60% | ― | -42.51% | -481.03% |
* Healthcare Sector Average
HEWA
HealthWarehouse
0.06
-0.08
-57.35%
PETS
Petmed Express
1.22
-1.44
-54.14%
NDRA
ENDRA Life Sciences
4.80
-0.50
-9.43%
LFMD
LifeMD
2.13
-4.01
-65.31%
KTTA
Pasithea Therapeutics Corp
0.40
-0.31
-43.10%
HSCS
Heart Test Laboratories, Inc.
3.14
-0.10
-3.09%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.